PharmTech Drug Digest 11.20
News|Articles|October 5, 2015

Merck Millipore Adds Protein Pegylation Services

Merck Millipore’s collaboration with celares GmbH launches pegylation services for protein-based therapeutics.

Merck Millipore, the life science business of Merck, announced a collaboration with celares GmbH to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The service includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities for pilot and subsequent commercial scale.

The services will leverage EMD Millipore’s functionalized PEG products of different molecular weight and activation chemistry, buffers, solvents and excipients, and unit operations employed during the pegylation process and subsequent purification including tangential and normal flow filtration and chromatography.

Source: Merck Millipore

 

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.